NCT01913847

Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension

Phase III Study to Evaluate Efficacy and Safety of HGP1207 in Patients With Pulmonary Hypertension Associated With Systolic Heart Failure

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 144 (estimated)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the safety and clinical efficacy of HGP1207 (Sildenafil) in subjects with pulmonary hypertension associated with systolic heart failure.

Conditions

• Pulmonary Hypertension
• Systolic Dysfunction

Interventions

Type	Name	Description
DRUG	Sildenafil	Oral sildenafil 20 mg TID for 12 weeks
DRUG	Placebo	Oral placebo TID for 12 weeks

Timeline

• Start date: 2013-09-01
• Primary completion: 2018-12-01
• Completion: 2018-12-01
• First posted: 2013-08-01
• Last updated: 2017-11-27

Locations

1 site across 1 country: South Korea